Abstract
Liver diseases that are caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), have become increasingly important in patients infected with the human immunodeficiency virus (HIV) as their life expectancy is getting longer with successful anti-HIV therapy. Due to their shared transmission routes, dual infection by HIV and HBV or HIV and HCV, and triple infection by all three viruses are fairly common and affect millions of people worldwide. Whereas the immunodeficiency caused by HIV enhances the likelihood of HBV and HCV persistence, hepatotoxicity associated with anti-HIV therapy can worsen the liver diseases associated with HBV or HCV persistence. Evidence suggests HIV infection increases the risk of HBV- or HCV-associated HCC risk although the precise mechanisms of enhanced hepatocarcinogenesis remain to be fully elucidated. Recent success in curing HCV infection, and the availability of therapeutic options effective in long-term suppression of both HIV and HBV replication, bring hope, fortunately, to those who are coinfected but also highlight the need for judicious selection of antiviral therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Thomas DL (2006) Growing importance of liver disease in HIV-infected persons. Hepatology 43(2 Suppl 1):S221–S229
Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G (2001) Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/Infectious diseases, in 1995 and 1997. Clin Infect Dis 32(8):1207–1214
Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P (2009) Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Int J Infect Dis. 13(3):302–306
Koziel MJ, Peters MG (2007) Viral hepatitis in HIV infection. N Engl J Med 356(14):1445–1454
WHO (2017) Global hepatitis report, 2017
Hu J (2016) Hepatitis B virus virology and replication. In: Liaw Y-F, Zoulim F (eds) Hepatitis B virus in human diseases. Humana Press, Springer Cham Heidelberg New York Dordrecht London, pp 1–34
Ganem D, Prince AM (2004) Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med 350(11):1118–1129
Slagle BL, Andrisani OM, Bouchard MJ, Lee CG, Ou JH, Siddiqui A (2015) Technical standards for hepatitis B virus X protein (HBx) research. Hepatology 61(4):1416−1424
Decorsiere A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK et al (2016) Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 531(7594):386–389
Yim HJ, Lok AS (2006) Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43(2 Suppl 1):S173–S181
Wright TL (2006) Introduction to chronic hepatitis B infection. Am J Gastroenterol 101(Suppl 1):S1–S6
Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30(12):2212–2219
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386(10003):1546–1555
Lavanchy D, Kane M (2016) Global epidemiology of hepatitis B virus infection. In: Liaw Y-F, Zoulim F (eds) Hepatitis B virus in human diseases. Humana Press, Springer Cham Heidelberg New York Dordrecht London, pp 187–203
Trepo C, Chan HL, Lok A (2014) Hepatitis B virus infection. Lancet 384(9959):2053–2063
Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436(7053):933–938
Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 3(2):47–52
Seeff LB (1999) Natural history of hepatitis C. Am J Med 107(6B):10S–15S
Park JS, Saraf N, Dieterich DT (2006) HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep 8(1):67–74
Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44(1 Suppl):S6–S9
Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT, Investigators HIVOS (2010) Prevalence of chronic hepatitis B virus infection among patients in the HIV outpatient study, 1996–2007. J Viral Hepat 17(12):879-86
Alexiev I, Alexandrova M, Golkocheva-Markova E, Teoharov P, Gancheva A, Kostadinova A et al (2017) High rate of hepatitis B and C coinfections among people living with HIV-1 in Bulgaria: 2010–2014. AIDS Res Hum Retroviruses 33(3):228–229
Martin-Carbonero L, Poveda E (2012) Hepatitis B virus and HIV infection. Semin Liver Dis 32(2):114–119
Sulkowski MS (2008) Viral hepatitis and HIV coinfection. J Hepatol 48(2):353–367
Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A et al (2005) Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis 191(7):1169–1179
Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM et al (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15(11):1661–1666
Gupta P, Hepatitis C (2013) Virus and HIV type 1 co-infection. Infect Dis Rep. 5(Suppl 1):e7
Sterling RK, Sulkowski MS (2004) Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin Liver Dis 24(Suppl 2):61–68
Liu Z, Hou J (2006) Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 3(2):57–62
Chemin I, Trepo C (2005) Clinical impact of occult HBV infections. J Clin Virol 34(Suppl 1):S15–S21
Tamori A, Nishiguchi S, Shiomi S, Hayashi T, Kobayashi S, Habu D et al (2005) Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol 100(8):1748–1753
Michalak TI, Mulrooney PM, Coffin CS (2004) Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 78(4):1730–1738
Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ et al (2006) Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130(4):1107–1116
Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127(5 Suppl 1):S56–S61
Branda M, Wands JR (2006) Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43(5):891–902
Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31(4):339–346
Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1):S35–S50
Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR, et al (2006) Trends in the incidence of cancer in Qidong, China, 1978–2002. Int J Cancer
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2004) Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127(5):1372–1380
El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5 Suppl 1):S27–S34
White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB (2017) Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 152(4):812–20 e5
Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044
Tradati F, Colombo M, Mannucci PM, Rumi MG, De Fazio C, Gamba G, et al (1998) A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The study group of the association of Italian hemophilia centers. Blood 91(4):1173–7
Liang TJ, Heller T (2004) Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S62–S71
Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22(33):5093–5107
Anzola M (2004) Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11(5):383–393
Guerrieri F, Belloni L, Pediconi N, Levrero M (2016) Pathobiology of Hepatitis B Virus-Induced Hepatocarcingenesis. In: Liaw Y-F, Zoulim F (eds) Hepatitis B virus in Human Diseases. Humana Press, Springer Cham Heidelberg New York Dordrecht London, pp 95–121
Cougot D, Neuveut C, Buendia MA (2005) HBV induced carcinogenesis. J Clin Virol 34(Suppl 1):S75–S78
Zhao LH, Liu X, Yan HX, Li WY, Zeng X, Yang Y et al (2016) Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun 7:12992
Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al (2016) HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151(5):986–98 e4
Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C et al (2005) Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54(8):1162–1168
Minami M, Daimon Y, Mori K, Takashima H, Nakajima T, Itoh Y et al (2005) Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 24(27):4340–4348
Hsu T, Moroy T, Etiemble J, Louise A, Trepo C, Tiollais P et al (1988) Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell 55:627–635
Moroy T, Marchio A, Etiemble J, Trepo C, Tiollais P, Buendia M (1986) Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature 324:276–279
Fourel G, Trepo C, Bougueleret L, Henglein B, Ponzetto A, Tiollais P et al (1990) Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 347(6290):294–298
Dejean A, Bougueleret L, Grzeschik KH, Tiollais P (1986) Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 322:70–72
Wang J, Chenivesse X, Henglein B, Brechot C (1990) Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343(6258):555–557
Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A et al (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The multivirc group. Hepatology 30(4):1054–1058
Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A et al (1999) Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29(4):1306–1310
Weinig M, Hakim JG, Gudza I, Tobaiwa O (1997) Hepatitis C virus and HIV antibodies in patients with hepatocellular carcinoma in Zimbabwe: a pilot study. Trans R Soc Trop Med Hyg 91(5):570–572
Tswana SA, Moyo SR (1992) The interrelationship between HBV-markers and HIV antibodies in patients with hepatocellular carcinoma. J Med Virol 37(3):161–164
Sherman M (2006) Optimizing management strategies in special patient populations. Am J Gastroenterology 101(Suppl 1):S26–S31
Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP et al (2004) Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 18(17):2285–2293
Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB (2005) The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 100(1):56–63
Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB (2004) Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med 164(21):2349–2354
Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V et al (2001) Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 96(1):179–183
Bruno R, Puoti M, Sacchi P, Filice C, Carosi G, Filice G (2006) Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. J Hepatol 44(1 Suppl):S146–S150
Smukler AJ, Ratner L (2002) Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr Opin Oncol 14(5):538–542
Goeser F, Glassner A, Kokordelis P, Wolter F, Lutz P, Kaczmarek DJ et al (2016) HIV mono-infection is associated with an impaired anti-hepatitis C virus activity of natural killer cells. AIDS 30(3):355–363
Hyun CB, Coyle WJ (2004) Hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem? South Med J 97(4):401–406
Chew KW, Bhattacharya D (2016) Virologic and immunologic aspects of HIV-hepatitis C virus coinfection. AIDS 30(16):2395–2404
Kew MC, Smuts H, Stewart A (2010) Does HIV infection enhance the hepatocarcinogenic potential of chronic hepatitis B virus infection? J Acquir Immune Defic Syndr 53(3):413–414
Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F et al (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22(12):1399–1410
Puoti M, Torti C, Bruno R, Filice G, Carosi G (2006) Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44(1 Suppl):S65–S70
Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al (2007) Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 47(4):527–37
Dharel N, Sterling RK (2014) Hepatitis B virus-HIV coinfection: forgotten but not gone. Gastroenterol Hepatol (N Y). 10(12):780–788
Iser DM, Lewin SR (2009) The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. Antivir Ther 14(2):155–164
Tanaka T, Imamura A, Masuda G, Ajisawa A, Negishi M, Tanaka S et al (1996) A case of hepatocellular carcinoma in HIV-infected patient. Hepatogastroenterology 43(10):1067–1072
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73
Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K (2004) High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 19(6):670–675
Hu J, Nguyen D (2004) Therapy for chronic hepatitis B: the earlier, the better? Trends Microbiol 12(10):431–433
van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA et al (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39(3):804–810
Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T et al (2005) Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. J Med Virol 75(4):491–498
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531
Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, et al (2005) Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 32(3):173–184
Shindo M, Hamada K, Oda Y, Okuno T (2001) Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 33(5):1299–1302
Tsuda N, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M et al (2004) Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 74(3):406–413
Meuleman P, Libbrecht L, Wieland S, De Vos R, Habib N, Kramvis A et al (2006) Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol 80(6):2797–2807
Yoon EJ, Hu KQ (2006) Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 3(2):53–56
Gaslightwala I, Bini EJ (2006) Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 44(6):1026–1032
Shmagel KV, Saidakova EV, Shmagel NG, Korolevskaya LB, Chereshnev VA, Robinson J et al (2016) Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection. HIV Med 17(8):581–589
Rivera MM, Soza A, Jazwinski A, Mi L, Kleiner DE, Zhao X et al (2015) HIV through the looking glass: insights derived from Hepatitis B. J Acquir Immune Defic Syndr 68(2):123–127
Page EE, Nelson M, Kelleher P (2011) HIV and hepatitis C coinfection: pathogenesis and microbial translocation. Curr Opin HIV AIDS 6(6):472–477
Li KW, Kramvis A, Liang S, He X, Chen QY, Wang C et al (2017) Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults. Virus Res 227:88–95
Sung FY, Lan CY, Huang CJ, Lin CL, Liu CJ, Chen PJ et al (2016) Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. Hepatology 64(3):720–731
Altavilla G, Caputo A, Lanfredi M, Piola C, Barbanti-Brodano G, Corallini A (2000) Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 157(4):1081–1089
Pol S, Lebray P, Vallet-Pichard A (2004) HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 38(Suppl 2):S65–S72
Revill P, Locarnini S (2016) The basis for antiviral therapy: drug targets, cross-resistance, and novel small nolecule inhibitors. In: Liaw Y-F, Zoulim F (eds) Hepatitis B virus in human diseases. Humana Press, Springer Cham Heidelberg New York Dordrecht London, pp 303–324
Soriano V, de Mendoza C, Pena JM, Barreiro P (2015) Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 16(2):179–186
Soriano V, Labarga P, de Mendoza C, Pena JM, Fernandez-Montero JV, Benitez L et al (2015) Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep 12(3):344–352
Sherman KE (2015) Management of the hepatitis B virus/HIV-coinfected patient. Top Antivir Med 23(3):111–114
Audsley J, Bent SJ, Littlejohn M, Avihingsanon A, Matthews G, Bowden S et al (2016) Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. AIDS 30(10):1597–1606
Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, et al (2017) Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients—French ANRS CO13 HEPAVIH cohort. J Hepatol 67(1):23–31
Meissner EG (2017) Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 33(3):120–127
Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsics T et al (2016) Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS 30(7):1039–1047
Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL et al (2011) Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 140(3):809–817
Macias J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, et al (2016) High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med 18(7):445–451
Khatri A, Dutta S, Dunbar M, Podsadecki T, Trinh R, Awni W et al (2016) Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Antimicrob Agents Chemother 60(5):2965–2971
Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG et al (2010) Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 28(21):3672–3678
van den Berg R, van Hoogstraten I, van Agtmael M (2009) Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 11(3):157–164
Pollack TM, Trang le TT, Ngo L, Cuong do D, Thuy PT, Colby DJ (2016) Response to hepatitis B vaccination among HIV-infected adults in Vietnam. J Virus Erad 2(2):102–6
Njom Nlend AE, Nguwoh PS, Ngounouh CT, Tchidjou HK, Pieme CA, Otele JM et al (2016) HIV-infected or -exposed children exhibit lower immunogenicity to hepatitis B vaccine in Yaounde, Cameroon: an appeal for revised policies in Tropical settings? PLoS ONE 11(9):e0161714
Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M et al (2013) Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine 31(7):1040–1044
Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ (2012) Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 12(12):966–976
Stapleton JT, Williams CF, Xiang J (2004) GB virus type C: a beneficial infection? J Clin Microbiol 42(9):3915–3919
Berzsenyi MD, Bowden DS, Roberts SK (2005) GB virus C: insights into co-infection. J Clin Virol 33(4):257–266
Tenckhoff S, Kaiser T, Bredeek F, Donfield S, Menius E, Lail A et al (2012) Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents. J Acquir Immune Defic Syndr 61(2):243–248
Xiang J, Wunschmann S, Diekema DJ, Klinzman D, Patrick KD, George SL et al (2001) Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 345(10):707–714
Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC et al (2001) Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 345(10):715–724
Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT (2004) Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363(9426):2040–2046
Revill P, Testoni B, Locarnini S, Zoulim F (2016) Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol 13(4):239–248
Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P et al (2016) International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med 22(8):839–850
Gjaerde LI, Shepherd L, Jablonowska E, Lazzarin A, Rougemont M, Darling K et al (2016) Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus-coinfected individuals from 2001 to 2014: a multicohort study. Clin Infect Dis 63(6):821–829
Peters L, Klein MB (2015) Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 10(5):297–302
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, 3rd, et al (2016) Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy Eras. Clin Infect Dis 63(9):1160–7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hu, J., Liu, K., Luo, J. (2019). HIV–HBV and HIV–HCV Coinfection and Liver Cancer Development. In: Meyers, C. (eds) HIV/AIDS-Associated Viral Oncogenesis. Cancer Treatment and Research, vol 177. Springer, Cham. https://doi.org/10.1007/978-3-030-03502-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-03502-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-03501-3
Online ISBN: 978-3-030-03502-0
eBook Packages: MedicineMedicine (R0)